TipRanks
Advertisement
Advertisement

CH:ROP Stock Latest News

Genentech, Breastcancer.org launch ‘About Damn Time’ campaign
The FlyGenentech, Breastcancer.org launch ‘About Damn Time’ campaign
1d ago
CHRO
Roche’s Genentech reports new data from Voyager study of Vabysmo
PremiumThe Fly
Roche’s Genentech reports new data from Voyager study of Vabysmo
1d ago
CHRO
Roche’s Genentech reports detailed results from evERA Breast Cancer study
PremiumThe Fly
Roche’s Genentech reports detailed results from evERA Breast Cancer study
1d ago
CHRO
Roche unit launches LightMix Newborn TREC/SMN1/HBB kit
PremiumThe Fly
Roche unit launches LightMix Newborn TREC/SMN1/HBB kit
2d ago
CHRO
Roche’s Genentech announces FDA approves NDA for fenebrutinib
PremiumThe Fly
Roche’s Genentech announces FDA approves NDA for fenebrutinib
2d ago
CHRO
Roche’s Genentech reports ‘positive’ results from Phase 3 Imagination study
PremiumThe FlyRoche’s Genentech reports ‘positive’ results from Phase 3 Imagination study
9d ago
CHRO
IONS
Zealand announces initiation of registrational Phase 3 ZUPREME program
Premium
The Fly
Zealand announces initiation of registrational Phase 3 ZUPREME program
10d ago
CHRO
Roche says Phase II obesity study met both primary endpoints
Premium
The Fly
Roche says Phase II obesity study met both primary endpoints
10d ago
CHRO
Roche reports European Commission approves Susvimo for nAMD
PremiumThe Fly
Roche reports European Commission approves Susvimo for nAMD
11d ago
CHRO
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
PremiumThe Fly
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
11d ago
AZN
BMY
U.S. weighs allowing most pharma licensing deals with China, Reuters says
PremiumThe Fly
U.S. weighs allowing most pharma licensing deals with China, Reuters says
14d ago
AZN
BMY
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents
PremiumThe Fly
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents
14d ago
CHRO
Genentech reports CELESTIMO study meets primary endpoint
PremiumThe FlyGenentech reports CELESTIMO study meets primary endpoint
15d ago
CHRO
Olema Oncology price target lowered to $30 from $48 at Stifel
Premium
The Fly
Olema Oncology price target lowered to $30 from $48 at Stifel
18d ago
AZN
CHRO
Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint
Premium
The Fly
Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint
19d ago
CHRO
Roche price target raised to CHF 380 from CHF 365 at HSBC
PremiumThe Fly
Roche price target raised to CHF 380 from CHF 365 at HSBC
22d ago
CHRO
Genentech granted Priority Review for Enspryng sBLA
PremiumThe Fly
Genentech granted Priority Review for Enspryng sBLA
22d ago
CHRO
Roche initiated with an Outperform at RBC Capital
PremiumThe Fly
Roche initiated with an Outperform at RBC Capital
24d ago
CHRO
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
PremiumThe Fly
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
1M ago
NVS
CHRO
mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley
PremiumThe FlymRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley
1M ago
MRK
BNTX
Roche announces new two-year data from Phase IIIb/IV SALWEEN study
Premium
The Fly
Roche announces new two-year data from Phase IIIb/IV SALWEEN study
1M ago
CHRO
Roche receives FDA approval for companion diagnostic tests for Ziihera
Premium
The Fly
Roche receives FDA approval for companion diagnostic tests for Ziihera
1M ago
CHRO
JAZZ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >